High capital allocations, low public relations. Long gestation businesses, short decision cycles. High absolute returns, low-to-nil asset attachment. This, in a nutshell, is Arun Kumar’s business philosophy. For someone who’s created three public pharma companies, incubated several smaller entities, and seals a new deal sooner than the ink on the previous one has dried, Kumar’s is an unusual wealth generation machine. One that is now being oiled for a different run.
Strides, SeQuent, Solara: An Indian entrepreneur’s ingenious pharma spiderweb
Arun Kumar’s first public company has 51 subsidiaries. His second has 21. His third, and most recent, is also likely to follow suit. But there’s a method and Midas touch to the madness
Strides Pharma has shifted focus from Australia to the US. A less-than-ideal move at a time when big Indian pharma companies are battling pricing and regulatory pressures
Founder Arun Kumar, known for making frequent deals, is sticking to his playbook. Is it working?
Solara, Kumar’s third public company, is fully capitalised for a global platform play with TPG Growth
Some placeholder companies have been created; his family business has begun investing after a three-year hiatus. Kumar wants to do “more with less”